These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 28035618)

  • 1. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.
    Otto W; Breyer J; Herdegen S; Eder F; Bertz S; May M; Mayr R; Lausenmeyer EM; Denzinger S; van Rhijn BW; Burger M; Hartmann A
    Int Urol Nephrol; 2017 Mar; 49(3):431-437. PubMed ID: 28035618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial-mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma.
    Breyer J; Gierth M; Shalekenov S; Aziz A; Schäfer J; Burger M; Denzinger S; Hofstädter F; Giedl C; Otto W
    World J Urol; 2016 May; 34(5):709-16. PubMed ID: 26394624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup.
    Byrne RR; Shariat SF; Brown R; Kattan MW; Morton RA JR; Wheeler TM; Lerner SP
    J Urol; 2001 May; 165(5):1473-9. PubMed ID: 11342899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Snail is an independent prognostic indicator for predicting recurrence and progression in non-muscle-invasive bladder cancer.
    Gou Y; Ding W; Xu K; Wang H; Chen Z; Tan J; Xia G; Ding Q
    Int Urol Nephrol; 2015 Feb; 47(2):289-93. PubMed ID: 25388353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anamnesis, Pathological Assessment, Therapeutic Features and Course of Disease: Retrospective Study on Clinical-Based Factors for Prediction of Cancer-Specific Survival of 378 Patients with Stage pT1 Urothelial Bladder Carcinoma].
    Breyer J; Otto W; Hartmann A; Bumes B; Bründl J; Gierth M; Bertz S; Denzinger S; Burger M; Lausenmeyer EM
    Aktuelle Urol; 2015 May; 46(3):221-6. PubMed ID: 26077306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infiltrative lamina propria invasion pattern as an independent predictor for cancer-specific and overall survival of instillation treatment-naïve stage T1 high-grade urothelial bladder cancer.
    Otto W; van Rhijn BW; Breyer J; Bertz S; Eckstein M; Mayr R; Lausenmeyer EM; Denzinger S; Burger M; Hartmann A
    Int J Urol; 2018 May; 25(5):442-449. PubMed ID: 29473226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
    Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
    Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of the epithelial-to-mesenchymal transition markers e-cadherin, vimentin and twist in bladder cancer.
    Zhao J; Dong D; Sun L; Zhang G; Sun L
    Int Braz J Urol; 2014; 40(2):179-89. PubMed ID: 24856504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of aquaporin 3 protein expression constitutes an independent prognostic factor for progression-free survival: an immunohistochemical study on stage pT1 urothelial bladder cancer.
    Otto W; Rubenwolf PC; Burger M; Fritsche HM; Rößler W; May M; Hartmann A; Hofstädter F; Wieland WF; Denzinger S
    BMC Cancer; 2012 Oct; 12():459. PubMed ID: 23043286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
    Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
    Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
    Mahnken A; Kausch I; Feller AC; Krüger S
    Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.
    Shariat SF; Kim JH; Ayala GE; Kho K; Wheeler TM; Lerner SP
    J Urol; 2003 Mar; 169(3):938-42. PubMed ID: 12576817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Krüppel-like factor 4 is a novel prognostic predictor for urothelial carcinoma of bladder and it regulates TWIST1-mediated epithelial-mesenchymal transition.
    Tseng WC; Chuang CW; Yang MH; Pan CC; Tarng DC
    Urol Oncol; 2016 Nov; 34(11):485.e15-485.e24. PubMed ID: 27519276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2 immunohistochemical expression as prognostic marker in high-grade T1 bladder cancer (T1G3).
    Bongiovanni L; Arena V; Vecchio FM; Racioppi M; Bassi P; Pierconti F
    Arch Ital Urol Androl; 2013 Jun; 85(2):73-7. PubMed ID: 23820653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer.
    Poyet C; Buser L; Roudnicky F; Detmar M; Hermanns T; Mannhard D; Höhn A; Rüschoff J; Zhong Q; Sulser T; Moch H; Wild PJ
    J Clin Pathol; 2015 Oct; 68(10):819-24. PubMed ID: 26251520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of KI-67 and CK20 for stage T1 urothelial bladder carcinoma: single-center analysis of eight biomarkers in a series of three hundred six patients.
    Otto W; Denzinger S; Fritsche HM; Burger M; Rößler W; Bertz S; May M; Hartmann A; Hofstädter F; Wieland WF; Eder F
    Clin Genitourin Cancer; 2013 Dec; 11(4):537-44. PubMed ID: 23850551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
    Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
    J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
    Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A;
    Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.